Lifecore Biomedical Inc (NASDAQ: LFCR) has reported a loss for its second fiscal quarter (ending November 30) of $-0.25 versus $0.47 for the same period a year ago — a decline of -153%. For the latest four quarters through November 30, E.P.S. were $-0.51 compared to $-1.55 a year ago.
Recent Price Action
Lifecore Biomedical Inc (NASDAQ: LFCR) stock closed at $6.66 on 1/2/25 after a major decline of -10.4%. Moreover, trading volume in this decline was exceptionally high at 366% of normal. Relative to the market the stock has been strong over the last nine months but has declined -5.3% during the last week.
Current PriceTarget Research Rating
Lifecore Biomedical has a current Value Trend Rating of F (Lowest Rating). The Value Trend Rating reflects very contradictory signals from PTR’s two proprietary measures of a stock’s attractiveness. Lifecore Biomedical has a very low Appreciation Score of 1 but a slightly positive Power Rating of 61, resulting in the Lowest Value Trend Rating.
Rating Review
In light of this new information and highly negative price change we are reviewing our current Overall Rating of F. This review will be completed in the next several days.
Be the first to comment